Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
John, thank you for the introduction to TMPS.
I caught your TMPS pieces/DD on http://ownthefloat.com/
I'm in agreement...The big picture is intact and just getting started.
Enjoy the ride, you've earned it!
The folks driving down TPMS are playing with fire, I wouldn't want to upset any of the heavy hitters running this ship.
Lack of patience and fear on missing out, only reason pps has made it into the 8's & 9's. Float has been locked for over a month.
I'm impressed how well it's held with lack of significant news related to INMG's core cannanet.tv. Night Flight is not a core material event.
Patience will be significantly rewarded$$. Wait until INMG & cannanet.tv release PR related to the core MJ related progress.
$$ Long INMG $$
Don't be so cheap HPFL...get that bid up...lol
Yes, the sizable investment was encouraging and impressive. I look forward to seeing them progress.
If it's as effective as they claim it to be, then I'm thrilled. But it's yet to generate any substantial value for the company. I want to see who's knocking on their door, as they've claimed in PR. I'm still waiting to see if they can generate any partnerships with other MJ bios and pharma by leveraging their bioinformatics platform.
I was encouraged when Revive Therapeutics discussed one of their operational highlights in their Q1 2017 PR announcement:
"A Term Sheet with InMed Pharmaceuticals for the Discovery and Development of Cannabinoid-Based Therapy Targeting Kidney Diseases"
https://finance.yahoo.com/news/revive-therapeutics-ltd-announces-results-110000907.html
At the very least, I think a deal in this capacity would help confirm some value within the bioinformatics division. We're still waiting for something.
Otherwise, I think they could gain momentum if they can move their drug candidates to trials within a reasonable time frame. I think we continue to consolidate for the time being.
KSHB I hear you. I'm excited to learn more about the deal too. It looks like they brought on an experienced guy to lead the new division.
Seems like their really expanding their product offerings into some new related areas. Their newest string of deals are interesting because they have a great customer base, where all of their new product offerings will be $relevant$ to both current and new customers.
I think sales growth will surprise investors over the next several quarters.
Agreed. What do you think about their Bioinformatics Platform?
KSHB Quietly developing their brand to drive in multiple sources of significant revenue. I love these deals, because they already have a solid customer base who will be interested in adding to their current orders, and the're expanding to gain new customers in new areas of the industry.
Brilliant moves in my opinion. Investors are really slow to see the value in this sleeping giant.
Here's their latest addition:
[url]
https://finance.yahoo.com/news/kush-bottles-opens-product-development-123000907.html[/url][tag]insert-text-here[/tag]
[url]
https://www.terpsonterps.com/[/url][tag]insert-text-here[/tag]
I think you're right with this. Tiny float. Chart looks like it's setting up nicely with higher lows. Pure speculation, but it looks like it wants to take a leg higher.
Lots of sticky fingers out there today. No one wants to sell their shares. Curious if tomorrow plays out the same way. I suspect several material events will begin to surface as we get closer to MJAC.
INMG is completely flying under the radar.
Yesterdays announcement was interesting. Great to see how they intend to start building up traffic. Night Flight brings in approximately 60k visitors a month to their website, and I'm willing to guess the demographics of their visitors will be intrigued by INMG's Cannanet.tv content. I wouldn't be surprised to see more libraries of content come on board. It's a win / win for all parties involved.
lol...looks like one of the flippers is trying to get back in with their 2.7M share bid @.009...good luck, but I think you're gonna have to raise that bid.
I just subscribed. Thanks for the heads up GG! The format change looks exciting.
SR has been spot on. I doubt Night flight will be the only form of distribution, and I suspect more deals are in the works....lots of them too. Demand for this sort of content is only expected to grow exponentially for years to come.
We're just getting started in the top of the first inning here. Potential is here. After this morning, it's obvious many of so called "longs" are very short-sighted, and as another poster claimed earlier..."you will be chasing to get into INMG from here"
There's no doubt that many of the self proclaimed "longs" and "strong hands" on this board, are flippers or just have no clue what they are.
SR has been right on this one. Stay long if you want to be rewarded with substantial gains.
About 2.5 to 3 million shares out of weak hands....win for the longs!
lol...I added too @ .0101. That's a gift in my opinion. Although the deal is somewhat muted, progress is being made. I wouldn't want to go into MJAC without a substantial amount of shares. If you can still get them at these levels, keep taking them from weak hands.
I didn't see anything stating if this was an exclusive deal with night flight? Is anyone familiar with night flight tv?
These guys are correct. Black Swan, LLC is not properly registered with the state of Nevada. Hopefully it's an over site on Black Swan, LLC's part.
The only question I have: Will the check's clear and are they paying on time?
I don't think it's gonna take 3-6 months for some significant shareholder appreciation, but I'm also not holding my breathe for it to happen this week. This week & next week is accumulation opportunity for those who see potential value here. Those who ran into buy in the last 2 weeks, were just rift raft hoping to turn a quick buck on "Major PR Release". As you can see, most who bought have already exited the building.
That's their game, but it's not mine. Stay in your lanes, stay discipline and don't get distracted by others who will come and go.
I wouldn't hold your breathe for a PR release from Mary Jane Berlin. I doubt anything huge happened there. Probably just meet and greets, and an exchange of content/partnership ideas. These deals can take weeks/months to develop, and I doubt anything was closed over the weekend. DD takes time for all parties involved. And if you look at the history of PR releases, they are few and far between.
Nothing has changed over the past 2-3 weeks. INMG will continue to consolidate and lower prices are imminent, and this is great for long term holders..Let the flippers from the last couple of weeks run along and through in their towels...they are not the people you want buying anyways..I don't know about you, but I love when things go on sale...especially when it's something I want.
Patience will pay off for the real shareholders. I love 20% off, but 30-40% is my sweet spot. I just bought a couple new golf clubs for 40% at dicks yesterday...and I could be happier!
Good news keeps coming in: http://leadingedgematerials.com/leading-edge-materials-intersects-further-lithium-mineralization-at-shallow-depth-at-bergby-sweden/
Looks like we should get a breakout soon!
June 19, 2017
MyDx Enters Into An ~$80,000 MyDx360
SaaS Licensing And Services Agreement
With Retailer BlackSwan
BlackSwan enters the Delivery Pen and Supplements Markets with
I+huntr Brand, Tailored for Performance Athletes, Powered by
MyDx360
SAN DIEGO, June 19, 2017 /PRNewswire/ --MyDx, Inc. (OTCQB: MYDX), a science and
technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld
chemical analyzer designed for cannabis professionals and retail consumers to correlate
the chemical profile of cannabis with how it makes them feel and which ailments they
report it alleviates, today announced a definitive agreement with BlackSwan, a developer
and retailer of custom vaporizers, to provide a community engagement software platform
to support its new product development initiatives under the terms of MyDx360.
Licensing Agreement Provides for Branding on Multiple Delivery Mechanisms
As part of the MyDx360 agreement, BlackSwan chose from one of MyDx's base chemical
formulations that best alleviated pain and inflammation according to the MyDx community.
From there, MyDx software enabled BlackSwan to "boost" that formula by changing
various cannabinoid and terpene parameters as well as other natural organic terpenes to
come to a final formula uniquely formulated by BlackSwan.
"This uniquely positions MyDx at the center of a revolution in how therapies are developed
utilizing chemicals found in cannabis and other naturally occurring plants. The MyDx360
platform makes it incredibly easy for market players to create new high quality tailored
formulations that can support their customer's needs. It also speaks to our ability as a
company to execute on our vision of creating a brand centric ecosystem powered by
community driven data. We look forward to supporting BlackSwan and the development
of the I+huntr brand personalized for high performance athletes and powered by
MyDx360," said Daniel Yazbeck, CEO of MyDx.
MyDx will continue to work with BlackSwan to support the development of new
formulations, which will be manufactured in the form of concentrates via state licensed
suppliers, and then delivered via MyDx's hardware, the ECO Smart Pen, and supplements
tailored to performance athletes. Once products have been delivered via MyDx's
manufacturing partnerships, the MyDx App will provide customer-engagement support to
acquire and analyze user feedback.
BlackSwan to Launch I+huntr Brand for High Performance Athletes
BlackSwan intends to market its unique formula under theI+huntr Brand to athletes
seeking alternatives to traditional opioid pain killers, among other ailments – an area the
company has significantly researched and thinks will grow into a substantial market,
especially as cannabinoid and other natural plant extract therapeutic use becomes more
widely accepted.
"We see this as an opportunity to develop a quality product and reduce the time to market
for the Delivery Pen and Supplement markets with targeted formulas we can brand and
sell," said BlackSwan CEO, Jeff Lau. "Moreover, we think there's significant opportunity in
this space to differentiate, capture market share and truly offer products that might help
alleviate specific ailments or side effects as defined by cannabis users and we're excited
to be working with the foremost authority on the subject in MyDx."
BlackSwan intends to have its products available for sale by January of 2018 with an initial
launch in the State of California, which represents close to 50% of the US cannabis
market. The company will offer its products in three distinct organic flavors (Orange Crush,
Blueberry and Mint), which will target various levels of recovery based upon cannabis user
formulas addressing their anxiety, pain management, recovery, and performance.
Cannabis Offers the Potential to Curb the Opioid Crisis Among Athletes
Addiction to pain killers is Youth Athletics' dirty little secret as young men and women vie
for prestigious college athletic scholarships and eventually elite status as professionals.
The abuse is well documented among athletes; however, little to no alternatives have
been provided that have the dual potential of alleviating their addictions as well as
providing inflammation and pain relief.
In an article by Sports Illustrated titled "How painkillers are turning young athletes into
heroin addicts", SI covered the tragic story of Roman Montano, a high school baseball
Phenom who was destined to be a star and, at one time, started over current Phillies Ace,
Ken Giles. Unfortunately, that story would never came true. A foot injury would lead to an
OxyContin addiction that would eventually transform him into a heroin addiction. That
heroin addiction would end that young man's life at a tender age of 22.
Unfortunately, we'll never know what might have been had Roman remained healthy, and
it's a story that hasn't been lost on BlackSwan CEO Jeff Lau.
"This is a topic that many people aren't talking about because it's a bit taboo, there's big
money involved and there's immense pressure to perform when injured," said BlackSwan
CEO, Jeff Lau. "Fortunately, the chemicals in cannabis have shown tremendous promise
in its ability to alleviate pain and inflammation in much of the same way as opioids, but
without the propensity for addiction, and with the potential for additional health benefits,
which are still undergoing studies."
The reality is that since cannabis is still a Scheduled I drug federally, many people who
would otherwise have alternatives to opioids can't get them. Moreover, if they decided to
use cannabis as an alternative, then they could potentially violate substance abuse
policies that currently exist in all levels of athletics and that could have severe
consequences, financial or otherwise.
The good news is that formulating cannabis with ingredients that have healing factors
without the "high" associated with cannabis (namely CBD and various Terpenes) is
gaining wider-acceptance and could potentially one day be the drawing line that many
athletes have hoped for. This is exactly the area BlackSwan intends to focus on with the
help of MyDx.
CBD and Terpene Formulations Have Demonstrated Anti-Inflammation Properties
CBD has been reported by various publications and research reports to be a cannabinoid
known for its extensive therapeutic value. It is a powerful anti-epileptic, anti-depressant,
anti-inflammatory, anti-nauseate, sleep aid, muscle relaxant, sedative and antiproliferative.
Some people call it the "Miracle Drug." What makes it popular among users is
its non-psychotropic properties, meaning it does not give you the "high" that you feel when
you consume THC. As a result, it can also be administered at relatively high doses without
any known undesired psychological side effects.
Terpenes are naturally occurring compounds that give plants and flowers their unique
smell. In cannabis plants, terpenes originate from the same glands that produce THC,
CBD and other cannabinoids and assist the effects of cannabinoids by also interacting
with endocannabinoid system in people, otherwise known as the "Entourage Effect."
Terpenes with anti-inflammatory and pain reducing properties include Caryophyllene,
Linalool, and Pinene, to name a few.
To learn more about the cannabinoids, terpenes, the entourage effect, and the science of
how they all interact to impact our physiology, please refer to Part 3: Cannabis 2.0 on
page 17 of the MyDx White Paper.
About MyDx, Inc.
MyDx, Inc. (OTCQB: MYDX) is a chemical detection and sensor technology company
based in San Diego, California whose mission is to help people Trust & Verify® what they
put into their minds and bodies. The Company developed MyDx®, a patented, affordable
portable analyzer that provides real-time chemical analysis and fits in the palm of the
user's hand. The multi-use MyDx analyzer leverages over a decade of established
chemical detection technology to measure chemicals of interest. The Company owns a
substantial and growing intellectual property portfolio of patents covering its technology.
The MyDx AquaDx®, OrganaDx
(TM) and CannaDx
(TM) sensors are now commercialized,
and the AeroDx® application is next in line. All sensors will be compatible with a MyDx
App that empowers consumers to live a healthier life by revealing the chemical
composition of what they eat, drink and inhale. For more information, please
visit www.cdxlife.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section
27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities
Exchange Act of 1934, as amended. Statements may contain certain forward-looking
statements pertaining to future anticipated or projected plans, performance and
developments, as well as other statements relating to future operations and results. Any
statements in this press release that are not statements of historical fact may be
considered to be forward-looking statements. Words such as "may," "will," "expect,"
"believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or
variations of these or similar words, identify forward-looking statements. These forwardlooking
statements by their nature are estimates of future results only and involve
substantial risks and uncertainties, including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements, development of
new products, our ability to complete our product testing and launch our product
commercially, the acceptance of our product in the marketplace, the uncertainty of the
laws and regulations relating to cannabis, the impact of competitive products or pricing,
technological changes, the effect of economic conditions and other uncertainties detailed
from time to time in our reports filed with the Securities and Exchange Commission,
available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.
Investor Contact:
MyDx Shareholder Communications
800.814.4550 ext. 4
ir@cdxlife.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/newsreleases/mydx-enters-into-an-80000-mydx360-saas-licensing-and-services-agreementwith-retailer-blackswan-300475524.html
SOURCE MyDx, Inc
Checking out some live FB feeds at the Mary Jane Berlin Festival.
https://www.facebook.com/pg/maryjane.berlin/posts/?ref=page_internal
Great point. Seems like a major material filing should be highlighted on the sticky board.
MYDX's Database will fuel it's future growth....we're not even out of the first inning with this one. It's all in the data. Industry execs need this data to grow & develop their businesses.
Okay, I hear you. The sooner the better, but obviously you have no control over it. At this point I'm happy to grab cheaper shares, and I wouldn't mind picking more up sub penny if the announcement is slow to come out next week too....because that's where we're headed if news doesn't show up on monday or tues.
Didn't Tom tell you he was going to release something this week. You spent all last week telling everyone....re-posting your email with tom....over and over and over.
Data, data & more data.
MYDX's database will be one of the most valuable databases in the industry!
Yes, this was confirmed yesterday.
MYDX going higher!
Entering, focusing and promoting in the Canadian market is a smart move, but it's not what I'm most excited about.
My attention is on the data, MYDX's database, the consumers and users who will continue to add to the database(at little / no cost for MYDX), and the companies who need these data points for their growth, research, studies, product development, patient and doctor communication, consumer engagement and consumer feedback.
The deal with Black Swan, although not big in $$$ terms, is HUGE in terms of confirming/legitimizing the value of MYDX's data points.
It's all about the data. Why do you think facebook & google are the top advertising platforms in the world? They have the data which consumers freely give them each and everyday.
I'm not saying MYDX will ever be a google or facebook, but they are also collecting data at very little cost, and it will grow into a very valuable asset within the pot industry.
That's why i've bought several million shares.
MYDX is going higher.
Yes, many claims were made this deal was never going to happen. Guess what, it did...and it was made possible by sharing the data in a non-exclusive agreement. What are your thought?
Very Interesting Deal Here: MYDX leveraging the database and access to the data. Database value being confirmed.
http://ir.cdxlife.com/all-sec-filings/content/0001213900-17-006505/f8k060917_mydxinc.htm ...see the 8k filing
Continued Bullishness....nice little run!
In agreement regarding strength of partnership with Revive, but think a deal in this capacity would help legitimatize their Bioinformatics division. InMed claims it to be one of their most valuable assets. If true, the potential could be significant. For now, we wait and see.
Interesting you mention the deal expired a long time ago. I'm curious if Revive maybe misleading investors of progress?
On May 25th 2017-Revive mentions the potential deal in the Q1 2017 PR release. (20 days /three weeks ago)
Revive Therapeutics Ltd. Announces Results for the Three and Nine Months Ended March 31, 2017
https://finance.yahoo.com/news/revive-therapeutics-ltd-announces-results-110000228.html
The 4th bullet-point on their Operational Highlights states:
"A Term Sheet with InMed Pharmaceuticals for the Discovery and Development of Cannabinoid-Based Therapy Targeting Kidney Diseases"
That's where I got my PumPy info
One of many deals expected. We know they're in talks with revive Pharma too.
Seems silly to not have some sort of sponsorship or a presentation booth at a major expo/festival in the market they're looking to launch into. They are planning on launching in Germany, right?
Hopefully there's more facts we don't know about or maybe over-looking regarding the festival. We need an update with strategic plans. The possibilities seem endless with different directions they may pursue. I just hope this isn't an oversight or misstep. Although, I wouldn't mind adding closer to .005.
Interesting to see MYDX on Amazon now.
https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Daps&field-keywords=mydx
The other one I really like is TLGRF...Worth a look, under the radar w/substantial progress being made, and some big money getting behind it.
http://www.talgaresources.com/irm/content/asx-announcements.aspx?RID=8
Very Surprised to see the lack of interest in Leading Edge Materials. Some of the biggest potential in the space. Not to mention the range it's been in for the past couple of weeks $0.40 to $0.43. It's a a big buying opportunity in my opinion.